⌛ Did you miss ProPicks’ 13% gains in May? Subscribe now & catch June’s top AI-picked stocks early.Unlock Stocks

AstraZeneca approached Gilead about potential merger - Bloomberg News

Published 06/07/2020, 04:23 AM
Updated 06/07/2020, 10:15 AM
© Reuters. FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen during the outbreak of the coronavirus disease (COVID-19), in California
MSFT
-
LLY
-
MRK
-
GILD
-
AZN
-
PFE
-

By Paul Sandle and Pamela Barbaglia

LONDON (Reuters) - Britain's AstraZeneca Plc (L:AZN) has approached U.S. rival Gilead Sciences Inc (O:GILD) about a possible merger that would form one the world's largest drug companies, Bloomberg News reported on Sunday, citing people familiar with the matter.

Any deal would unite two of the companies at the forefront of the industry's efforts to fight the new coronavirus and could be politically sensitive as governments seek control over potential vaccines or treatments.

AstraZeneca contacted Gilead last month, but the U.S. firm was not interested in combining with another big pharmaceutical company, the Bloomberg report https://bloom.bg/3h2GU9e said.

A spokeswoman for AstraZeneca said the company does not comment on rumors or speculation.

Gilead, the world's largest maker of HIV drugs, did not immediately respond to a request for comment.

If combined, the two companies would have a market capitalization of about $232 billion, based on Friday's closing stock levels.

That would exceed Merck & Co (N:MRK) and Pfizer (N:PFE) at $207 billion and $200 billion respectively.

Two sources familiar with AstraZeneca's thinking questioned the rationale of a tie-up, telling Reuters Gilead's remdesivir for COVID-19 patients was insufficient to justify pursuing a multi-billion deal that would detract from AstraZeneca's work on a coronavirus vaccine.

One of the sources questioned the timing. Given the potential impact a successful vaccine would have on AstraZeneca's share price, it does not need the additional strain of pursuing a record-breaking deal, especially when travel constraints make face-to-face meetings difficult.

AstraZeneca's top-selling product is its lung cancer drug Tagrisso, which generated revenues of $982 million in the first quarter.

Gilead's biggest blockbuster is HIV drug Biktarvy, with sales of $1.69 billion in the first quarter.

Gilead, AstraZeneca and other drugmakers, including Eli Lilly and Co (N:LLY), Pfizer Inc (N:PFE) and Merck & Co Inc (N:MRK), are racing to develop vaccines or treatments for COVID-19, the respiratory illness caused by the novel coronavirus.

More than 6.90 million people have been reported infected with the coronavirus globally and 399,025 have died, a Reuters tally showed on Sunday.

It is unclear whether a vaccine will work, but AstraZeneca's partnership with Oxford University to develop one is among a handful of initiatives U.S. President Donald Trump's COVID task force has backed.

Gilead has also been in the vanguard of COVID-19 treatments.

Its remdesivir antiviral is the first drug to lead to improvement in COVID-19 patients in formal clinical trials.

The drug has been cleared for emergency use in COVID-19 patients in countries including the United States and South Korea and could bring in more than $7 billion in annual sales for Gilead by 2022 if governments seek to stockpile it against future outbreaks, SVB Leerink has estimated.

© Reuters. FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen during the outbreak of the coronavirus disease (COVID-19), in California

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.